Cancer Cachexia Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AEterna Zentaris, Pfizer, Incyte, Smartfish, Caelus, Helsinn

 Breaking News
  • No posts were found

Cancer Cachexia Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AEterna Zentaris, Pfizer, Incyte, Smartfish, Caelus, Helsinn

September 11
23:20 2023
Cancer Cachexia Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AEterna Zentaris, Pfizer, Incyte, Smartfish, Caelus, Helsinn
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Cancer Cachexia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Cancer Cachexia Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Cancer Cachexia Market. 

The Cancer Cachexia Pipeline report embraces in-depth commercial, regulatory, and Cancer Cachexia clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Cancer Cachexia drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Cancer Cachexia Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Cancer Cachexia treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Cancer Cachexia therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Cancer Cachexia companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Cancer Cachexia drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Cancer Cachexia therapeutic market.

Cancer Cachexia Therapeutics Landscape

Currently, the potential treatment options available for cancer cachexia include Nutritional counseling or appetite stimulants, Cytokine-based therapeutic approaches, and Anabolic Steroids. Despite a lack of data from large clinical trials to guide the treatment of people with cachexia, a handful of hospitals have dedicated cancer cachexia programs. The staff that run these programs rely on the evidence from published studies of managing cancer cachexia and best practices developed at their institutions and others.

There are approx. 15+ key companies developing therapies for Cancer Cachexia.  The dynamics of the Cancer Cachexia Therapeutics Market are anticipated to change in the coming years owing to the positive outcomes of some of the rare candidates during the development stage by key players, such as Actimed Therapeutics (ACM-001), AveoOncology (AV-380), Pfizer (PF 06946860), Extend Biosciences (EXT418) and others that are under early phase of clinical development have the potential to create a significant positive shift in cancer cachexia market size.

Currently, AEterna Zentaris is leading the therapeutics market with its Cancer Cachexia drug candidates in the most advanced stage of clinical development.

Cancer Cachexia Companies Actively Working in the Therapeutic Market Include:

  • AEterna Zentaris

  • Pfizer

  • Incyte Corporation

  • Smartfish AS

  • NGM Biopharmaceuticals

  • Caelus Health

  • Helsinn Therapeutics/Ono Pharmaceutical

  • Aphios Corporation

  • Actimed Therapeutics

  • Ildong Pharmaceutical

  • Tetra Biopharma

  • Aveo Oncology

And Many Others

Emerging and Marketed Cancer Cachexia Drugs Covered in the Report Include:

  • Macimorelin: AEterna Zentaris

Macimorelin (AEZS 130) is an orally active, small-molecule, being developed by AEterna Zentaris for the diagnosis of adult and pediatric growth hormone deficiency (AGHD; PGHD) [somatotropin deficiency in development table] and for the treatment of cachexia associated with chronic diseases, such as AIDS and cancer. Macimorelin was approved by the FDA in December 2017 under the market name Macrilen for oral solution. 

  • PF- 06946860: Pfizer

PF- 06946860 is a Growth Factor Blocker being investigated in the Phase I stage of development. A 6-week double-blind study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite has been initiated to find out how participants with advanced cancer and anorexia feel after receiving repeated doses injected under the skin.

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Cancer Cachexia Companies Working in the Market @

Analysis of Emerging Cancer Cachexia Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Cancer Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Cancer Cachexia Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Cancer Cachexia Treatment Patterns

4. Cancer Cachexia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Cancer Cachexia Late Stage Products (Phase-III)

7. Cancer Cachexia Mid-Stage Products (Phase-II)

8. Cancer Cachexia Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Cancer Cachexia Discontinued Products

13. Cancer Cachexia Product Profiles

14. Major Cancer Cachexia Companies in the Market

15. Key Products in the Cancer Cachexia Therapeutics Segment

16. Dormant and Discontinued Products

17. Cancer Cachexia Unmet Needs

18. Cancer Cachexia Future Perspectives

19. Cancer Cachexia Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Urinary Incontinence Market

“Urinary Incontinence Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Urinary Incontinence market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Urinary Incontinence market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles